Mithra releases invitation to its extraordinary securities holders’
meeting
Mithra
releases invitation to its extraordinary securities holders’
meeting
Liege, Belgium, 06 November 2023 – 17:45
CET – Mithra (Euronext Brussels: MITRA), a company
dedicated to Women’s Health announces today that it has published
and issued an invitation to its announced1 and conditionally
planned for extraordinary securities holders’ meeting that will be
held on Thursday, 23 November 2023, at
2:00 PM (CET).
The notice for the extraordinary general meeting
(EGM), including a description of the formalities to participate at
the meeting, is available on the website investors.mithra.com.
Admission requirements
As referred in the meetings' invitation
published in the Belgian press, the right to participate in the EGM
and to vote is subject to the prior registration of the shares
under the relevant shareholder’s name by 17 November
2023 at midnight (CET) (the
"Record Date"), either by way of registration on
the company’s share register, or either by way of registration in
book entry form in an account held with a settlement institution or
a certified account holder, without taking into account the number
of shares held by the shareholder at the day of the EGM. Only
persons who are shareholders on the Record Date are entitled to
vote at the EGM.
The shareholders must indicate their willingness
to participate in the EGM by 17 November 2023 at
the latest. This must be done by email to
corporate.secretary@mithra.com, or by mail marked for the attention
of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue
Saint-Georges in 4000 Liège.
Right to ask questions
The directors will answer questions that are
asked by the shareholders in writing, before the meeting and
concerning the agenda, in accordance with legal provisions. These
questions may be asked prior to the EGM by email via
corporate.secretary@mithra.com or by mail marked for the attention
of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue
Saint-Georges in 4000 Liège. These questions must be received by
the Company by 17 November 2023 at the latest.
Further information relating to the
above-mentioned rights and the modalities for exercising them are
available on the Company's website (www.mithra.com).
Proxies
Shareholders wishing to be represented at the
meeting by a proxy holder must send the completed and signed2 proxy
form to the Company on 17 November 2023 at the
latest, by email, fax or mail to Mithra’s headquarters.
Further information on the exercise of this
right is available on the Company’s website (www.mithra.com). The
proxy and voting forms may be obtained on the Company's website
(www.mithra.com) or upon request at the Company's registered
office, or by email to corporate.secretary@mithra.com.
Shareholders wishing to be represented must
comply with the registration and confirmation procedure described
above.
Available documents
All documents concerning the special and
extraordinary general meetings that are required by law to be made
available to shareholders as well as the text of the amended
articles of association following the approval of the amendments
proposed on the agenda may be consulted on the Company's website
(www.mithra.com) as from 06 November 2023. As from
the same date, shareholders have the right to consult these
documents on business days and during normal office hours, at the
Company's registered office and/or, upon display of their
securities, obtain copies of these documents free of charge.
Requests for copies may also be made, free of
charge, by mail (writing) marked for the attention of Mithra
Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à
4000 Liège, or by email to corporate.secretary@mithra.com.
For more information, please
contact:
Mithra Pharmaceuticals SAAlex Sokolowski, PhDHead
of Investor Relationsinvestorrelations@mithra.com+32 (0)4 349 28
22 |
Frédérique DepraetereCommunications Directorinfo@mithra.com +32
(0)4 349 28
22 |
|
About Mithra
Mithra Pharmaceuticals SA (Euronext: MITRA) is a
Belgian biopharmaceutical company dedicated to transforming Women’s
Health by offering new choices through innovation, with a
particular focus on contraception and menopause. Mithra’s goal is
to develop products offering better efficacy, safety and
convenience, meeting women’s needs throughout their life span.
Mithra explores the potential of the unique native estrogen
estetrol in a wide range of applications in women health and
beyond. After having successfully launched the first estetrol-based
product in 2021, the contraceptive pill ESTELLE®, Mithra is now
focusing on its second product DONESTA®, the next-generation
hormone therapy. Mithra also offers partners a complete spectrum of
solutions from early drug development, clinical batches and
commercial manufacturing of complex polymeric products (vaginal
ring, implants) and complex liquid injectables and biologicals
(vials, pre-filled syringes or cartridges) at its technological
platform Mithra CDMO. Active in more than 100 countries around the
world, is headquartered in Liège, Belgium. www.mithra.com
ESTELLE® and DONESTA® are registered trademarks
of Mithra Pharmaceuticals or one of its affiliates.
Important information
The contents of this announcement include
statements that are, or may be deemed to be, "forward-looking
statements". These forward-looking statements can be identified by
the use of forward-looking terminology, including the words
"believes", "estimates," "anticipates", "expects", "intends",
"may", "will", "plans", "continue", "ongoing", "potential",
"predict", "project", "target", "seek" or "should", and include
statements the Company makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks
and uncertainties and readers are cautioned that any such
forward-looking statements are not guarantees of future
performance. The Company's actual results may differ materially
from those predicted by the forward-looking statements. The Company
undertakes no obligation to publicly update or revise
forward-looking statements, except as may be required by law.
Subscribe to our mailing list on investors.mithra.com to receive
our press releases by email or follow us on our social media
:Linkedin • X • Facebook |
1 Convening Notice of Mithra’s 30 October
SGM/EGM
2 The form must be signed in writing or
electronically, with a qualified electronic signature within the
meaning of Regulation (EU) No 910/2014 of the European Parliament
and of the Council of 23 July 2014 on electronic identification and
trust services for electronic transactions in the internal market
and repealing Directive 1999/93/EC, as amended
- 2023- 11-06_Mithra_Press-release_Mithra announces and invites
to 23 Nov EGM_FR Consilium Edit
Mithra Pharmaceuticals (TG:1TM)
Historical Stock Chart
From Nov 2024 to Dec 2024
Mithra Pharmaceuticals (TG:1TM)
Historical Stock Chart
From Dec 2023 to Dec 2024